Welcome to our dedicated page for Lifeway Food SEC filings (Ticker: LWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lifeway Foods turns milk into gut-healthy kefir, but its SEC disclosures are where you’ll spot the numbers behind every probiotic bottle. Investors often ask where to locate milk-price sensitivity, how much revenue the ProBugs kids line contributes, or whether new distribution in the UAE affects margins. Those answers sit inside dense 10-Ks and 10-Qs—documents that can stretch past 300 pages.
Stock Titan’s AI trims the reading list. Open the Lifeway Foods quarterly earnings report 10-Q filing and our algorithm highlights same-store sales growth, inventory levels, and commodity cost hedges. Need Lifeway Foods insider trading Form 4 transactions? Real-time alerts surface every executive stock move, giving you the complete Lifeway Foods Form 4 insider transactions real-time feed without sorting through EDGAR. You’ll also find plain-language cards that make Lifeway Foods SEC filings explained simply, from Lifeway Foods annual report 10-K simplified to Lifeway Foods 8-K material events explained.
Why dig this deep? Filings reveal how Lifeway manages dairy supply contracts, tracks live-culture quality controls, and prices its expanding international lineup. In the proxy you’ll see Lifeway Foods proxy statement executive compensation that links bonuses to sales of kefir and cheese, while our dashboard delivers Lifeway Foods earnings report filing analysis that compares gut-health SKUs quarter over quarter. For advanced monitoring, set watchlists to flag Lifeway Foods executive stock transactions Form 4 before product launches. From milk procurement footnotes to distribution-channel breakdowns, our AI turns regulatory text into actionable context so you can focus on the trends—not the paperwork.
Edward and Ludmila Smolyansky, owners of approximately 26% of Lifeway Foods (NASDAQ: LWAY), have filed a definitive Consent Statement (July 2 2025) to remove the current board and seat seven new directors. The pair say early shareholder outreach shows growing support.
- Governance dispute: The activists accuse the board of delaying the 2025 AGM, refusing to set a record date and adopting a poison pill after dismissing Danone’s unsolicited $27 per-share offer as inadequate.
- Director sell-off: Lead independent director Jason Scher sold 24,566 shares (~$600k at $24.23), leaving only one share and apparently breaching Lifeway’s 200% retainer stock-holding policy.
- Call to action: Shareholders are urged to sign WHITE consent cards; the full solicitation materials are available on the SEC website.
Schedule 13D/A (Amendment No. 24) – Lifeway Foods, Inc. (NASDAQ: LWAY)
The filing updates the ownership positions and intentions of the Smolyansky family and related trust. Three reporting persons disclose the following beneficial holdings, calculated against 15,203,241 outstanding shares as of 6 May 2025:
- Edward Smolyansky: 3,159,975 shares (20.8%) – sole voting power over 2,584,975 and shared voting power over 575,000.
- Ludmila Smolyansky: 940,166 shares (6.2%) – sole voting power over 865,166 and shared over 75,000.
- The Edward Smolyansky Trust 2/2/16: 1,233,333 shares (8.1%) – sole voting and dispositive power.
In aggregate, the group controls approximately 35.1 % of the reported outstanding shares.
Purpose of Transaction: On 2 July 2025 the filing persons launched a consent solicitation seeking to:
- Repeal any by-law amendments adopted after 24 Mar 2023.
- Remove current directors appointed on or after 15 Jun 2024.
- Elect seven nominees (including Edward and Ludmila Smolyansky) to the board.
- Amend the by-laws to bar employment of the CEO’s immediate family members.
They simultaneously issued a press release (Ex. 99.1) and, on 7 July 2025, demanded that Lifeway call its 2025 Annual Meeting “as promptly as practicable.”
Implications: The filing signals an activist campaign aimed at overhauling governance, replacing directors and restricting nepotistic practices. With a combined stake above one-third of shares outstanding, the group wields significant influence that could reshape Lifeway’s board composition and corporate strategy.